{
    "organizations": [],
    "uuid": "bdf3cfb61a2571c043fb9687640e815f56379bbd",
    "author": "Sumathi Reddy",
    "url": "https://www.wsj.com/articles/new-migraine-drugs-offer-hope-to-sufferers-1526658140",
    "ord_in_thread": 0,
    "title": "New Migraine Drugs Offer Hope to Sufferers",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Lisa DeLeonardo set a Google alert so she would know exactly when the first in a new class of migraine drugs was approved.\nIt happened Thursday, when the U.S. Food and Drug Administration approvedAmgen and Novartis’ application for erenumab, whose brand name is Aimovig. It’s an injectable drug touted as the first treatment designed specifically to prevent migraines, and is expected to be available to patients within a week for an annual price of $6,900. Three other similar treatments are expected to hit the market within... ",
    "published": "2018-05-18T19:42:00.000+03:00",
    "crawled": "2018-05-19T16:49:02.000+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "lisa",
        "deleonardo",
        "set",
        "google",
        "alert",
        "would",
        "know",
        "exactly",
        "first",
        "new",
        "class",
        "migraine",
        "drug",
        "approved",
        "happened",
        "thursday",
        "food",
        "drug",
        "administration",
        "approvedamgen",
        "novartis",
        "application",
        "erenumab",
        "whose",
        "brand",
        "name",
        "aimovig",
        "injectable",
        "drug",
        "touted",
        "first",
        "treatment",
        "designed",
        "specifically",
        "prevent",
        "migraine",
        "expected",
        "available",
        "patient",
        "within",
        "week",
        "annual",
        "price",
        "three",
        "similar",
        "treatment",
        "expected",
        "hit",
        "market",
        "within"
    ]
}